Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer

Journal of Immunotherapy

Volumn 19, Issue 2, 1996, Pages 142-148

  Curti, Brendan D ^a   Urba, Walter J ^b   Longo, Dan L ^a   Janik, John E ^a   Sharfman, William H ^a   Miller, Langdon L ^c   Cizza, Giovanni ^d   Shimizu, Masanao ^e   Oppenheim, Joost J ^a   Gregory Alvord, W ^a   Smith, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Cortisol; Interleukin 1; Pituitary hormones; Testosterone

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; HYDROCORTISONE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LUTEINIZING HORMONE; PROLACTIN; SOMATOSTATIN; TESTOSTERONE;

ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DRUG EFFICACY; DRUG SCREENING; FOLLITROPIN BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LUTEINIZING HORMONE BLOOD LEVEL; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SOMATOSTATIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT PLANNING;

EID: 9244232262     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199603000-00007     Document Type: Article

References (27)

1. March CJ, Mosley B, Larsen A, et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985;315:641-7.
2. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2:108-15.
3. Dinarello CA. Interleukin-1. Rev Infect Dis 1984;6:51-95.
4. Puri RK, Travis WD, Rosenberg SA. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo. Cancer Res 1989;49:969-76.
5. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MAJ. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 1985;76:2003-11.
6. Herman J, Dinarello CA, Kew MC, Rabson AR. The role of interleukin 1 (IL-1) in tumor-NK cell interactions: correction of defective NK cell activity in cancer patients by treating target cells with IL-1. J Immunol 1985;135:2882-6.
7. Imura H, Fukata J, Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol 1991;35:107-15.
8. Watanobe H, Takebe K. Intrahypothalamic perfusion with interleukin-1-beta stimulates the local release of corticotropin-releasing hormone and arginine vasopressin and the plasma adrenocorticotropin in freely moving rats: a comparative perfusion of the paraventricular nucleus and the me-dian eminence. Neuroendocrinology 1993;57:593-9.
9. Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987;238:524-6.
10. Honegger J, Spagnoli A, D’Urso R, et al. Interleukin-1 beta modulates the acute release of growth hormone-releasing hormone and somatostatin from rat hypothalamus in vitro, whereas tumor necrosis factor and interleukin-6 have no effect. Endocrinology 1991;129:1275-82.
11. 2 release to suppress pulsatile release of luteinizing hormone but not follicle-stimulating hormone. Proc Natl Acad Sci USA 1991; 88:2763-7.
12. Ferrari L, Kremers P, Batt AM, Gielen JE, Siest G. Differential effects of human recombinant interleukin-1 beta on cytochrome P-450-dependent activities in cultured fetal rat hepatocytes. Drug Metab Dispos 1992;20:407-12.
13. Fiers W, Brouckaert P, Goldberg AL, et al. Structure function relationship of tumour necrosis factor and its mechanism of action. Ciba Found Symp 1987;131:109-23.
14. Smith JW II, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 1993;328:756-61.
15. Crown J, Jakubowski A, Gabrilove J. Interleukin-1: biological effects in human hematopoiesis. Leuk Lymphoma 1993; 9:433-40.
16. Smith JW II, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992;10:1141-52.
17. Steis R, Smith J II, Janik J, et al. Phase I study of recombinant IL-1 beta (Syntex) [Abstract]. Proc Am Soc Clin Oncol 1991; 10:211.
18. Vadhan-Raj S, Kudelka AP, Garrison L, et al. Effects of interleukin-lα on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994; 12:707-14.
19. Watanobe H, Ishii M, Kudo T, Nagata A, Takebe K. A marked molecular heterogeneity of growth hormone (GH) detected in the plasma but not pituitary of a patient with acromegaly: comparison with other acromegalics and an implication for discrepant plasma levels of GH and insulin-like growth factor. J Endocrinol Invest 1992;15:381-6.
20. Vassilopoulou-Sellin R, Kudelka AP, Kavanagh JJ, Edwards CL, Vadhan-Raj S. Effects of interleukin-la administration on pituitary-adrenal and pituitary-thyroid axes function of patients with ovarian cancer. J Immunother 1995;17:109-13.
21. Naito Y, Fukata J, Nakaishi S, et al. Chronic effects of interleukin-1 on hypothalamus, pituitary and adrenal glands in rat. Neuroendocrinology 1990;51:637.
22. Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 1988;167:1708-12.
23. Janik JE, Miller LL, Longo DL, et al. Phase II trial of interleukin la and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 1996;88:44-9.
24. Shintani F, Kanba S, Nakaki T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 1993; 13: 3574-81.
25. Fukata J, Usui T, Naitoh Y, Nakai Y, Imura H. Effects of recombinant human interleukin-1 alpha,-1 beta, 2 and 6 on ACTH synthesis and release in the mouse pituitary tumour cell line AtT-20. J Endocrinol 1989;122:33-9.
26. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with in terleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
27. Curran RD, Ferrari FK, Kispert PH, et al. Nitric oxide and nitric oxide-generating compounds inhibit hepatocyte protein synthesis. FASEB J 1991;5:2085-92.